Research

BOSTON – Medisafe, a leading digital health company specializing in medication engagement, released the results of a new retrospective, pre- and post-claims study of 207 patients with multiple sclerosis (MS) and epilepsy using Medisafe to manage their medication regimen and overall health. The analysis showed an average annual cost reduction of $6,280 per MS patient…

Get the latest insights from industry leaders on how digital technologies and health care delivery can withstand changes in the market. Download the Market Pulse (free, no registration)  

Get the latest insights from industry leaders on how pharma can capture greater value from digital patient programs. Download the Market Pulse (free, no registration)

Download our latest research showing how supporting patient engagement is not only a growing strategic initiative for pharma companies but is proving to be an impactful value driver. In today’s competitive world of pharma brands, with a narrowing share of patients and contrasting engagement channels, advanced digital solutions offer new opportunities to create value and…

Komodo Health, a healthcare data and analytics firm, conducted an analysis using its Healthcare Map™ of 325 million U.S. patient journeys to examine the impact of Medisafe’s digital drug companion on patient adherence and time on. Using claims data and a 1:3 matching formula, Komodo compared patients enrolled in a biologic digital companion program against…

Read how Medisafe and Pleio joined forces to help engage patients in their treatment journey through the power of human+digital connection, using a compassionate approach for the digital age to drive better outcomes. Redesigning the Patient Activation Cycle. Through the combination of human support and digital platform engagement, more than 50% of patients choose to…

In response to the challenge that Medisafe users are more inclined to be adherent with medication management, Medisafe created a study with IQVIA to measure the impact that digital companions can have on a chronically non-adherent patient population. Medisafe’s study measured the impact of digital companions across three therapeutic areas: hypertension, major depressive disorder, and…

Read how Medisafe and Merck KGaA, Darmstadt, Germany joined forces to help patients better manage their disease and adhere to their prescribed medication regimen. Click here to download the case study (PDF). In just five months, Merck KGaA, Darmstadt, Germany increased adherence rates up to 20% by customizing digital medication programs. Download the study to…

The following originally appeared in Population Health News July 2017 issue (Volume 4, Issue 7), published by Health Policy Publishing, LLC. Objectives: Evaluate the impact of Medisafe on a cohort of patients with hypertension, hyperlipidemia or Evaluate the uses of digital technology for managing chronic illnesses  Program Description: Founded in 2012, Medisafe is a leading…

Further findings from Medisafe’s ongoing scientific study conducted by IQVIA was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 24th Annual International Meeting and showed clinically and statistically meaningful results across two standard healthcare industry adherence metrics: MPR, which tracks frequency of refill, where an MPR of 1.0 corresponds to a 100%…